Allison Bratzel
Stock Analyst at Piper Sandler
(2.23)
# 1041
Out of 5,240 analysts
34
Total ratings
62.50%
Success rate
29.17%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
argenx | Maintains: Overweight | 620 725 | 661.93 | 9.53% | 13 | Jan 7, 2025 | |
Travere Therapeutics | Maintains: Neutral | 12 22 | 17.7 | 24.29% | 2 | Nov 14, 2024 | |
Rigel Pharmaceutical... | Maintains: Neutral | 15 23 | 17.61 | 30.61% | 2 | Nov 14, 2024 | |
Ionis Pharmaceutical... | Maintains: Overweight | 65 62 | 33.49 | 85.13% | 1 | Nov 14, 2024 | |
Scholar Rock Holding | Maintains: Overweight | 28 42 | 44.48 | -5.58% | 3 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 20 22 | 11.08 | 98.56% | 2 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 4 4 | 4.11 | -2.68% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 8 20 | 3.14 | 536.94% | 4 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Overweight | 20 | 2.97 | 573.4% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 23 25 | n/a | n/a | 1 | Apr 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Overweight | 44 | 10.83 | 306.28% | 1 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 100 | 72.88 | 37.21% | 2 | Feb 8, 2023 |